Legend Biotech (LEGN) Stock Price, News & Analysis

Company Overview

Legend Biotech is a biotechnology company focused on developing cell therapies for cancer, with an emphasis on chimeric antigen receptor (CAR) T-cell treatments. Founded in 2014, the company is headquartered in Somerset, New Jersey, and conducts research and development activities in the United States and China.

Its lead product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. Legend developed the therapy with Janssen, now part of Johnson & Johnson’s Innovative Medicine business, which collaborates on its commercialization.

Legend’s pipeline includes additional investigational cell therapies for cancer. Through its collaboration and product development efforts, the company is working to bring its therapies to patients in multiple markets.

Key Stats

• Today's Range: $22.88 to $24.42
• 50-Day Range: $17.00 to $24.29
• 52-Week Range: $16.24 to $37.50
• Volume: 2.04 million shs
• Average Volume: 2.04 million shs
• Market Capitalization: $4.71 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $54.69
• Consensus Rating: Moderate Buy

Legend Biotech Stock Analysis - MarketRank™

Legend Biotech scored higher than 73% of companies evaluated by MarketBeat, and ranked 168th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Legend Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on no strong buy ratings, 9 buy ratings, 5 hold ratings, and 1 sell rating.

Upside Potential

Legend Biotech has a consensus price target of $54.69, representing about 125.2% upside from its current price of $24.29.

Amount of Analyst Coverage

Legend Biotech has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Legend Biotech are expected to grow in the coming year, from ($0.08) to $1.16 per share.

Price to Book Value per Share Ratio

Legend Biotech has a P/B Ratio of 4.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.18% of the float of Legend Biotech has been sold short.

Short Interest Ratio / Days to Cover

Legend Biotech has a short interest ratio ("days to cover") of 6.7.

Change versus previous month

Short interest in Legend Biotech has recently decreased by 15.15%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Legend Biotech does not currently pay a dividend.

Dividend Growth

Legend Biotech does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.59

News Sentiment

Legend Biotech has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Legend Biotech this week, compared to 5 articles on an average week.

Search Interest

Only 4 people have searched for LEGN on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

MarketBeat Follows

5 people have added Legend Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Legend Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $308,550.00 in company stock.

Percentage Held by Insiders

0.02% of the stock of Legend Biotech is held by insiders.

Percentage Held by Institutions

70.89% of the stock of Legend Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 11/10/2026
• Next Earnings (Estimated): 11/10/2026
• 8th Annual Wolfe Research Healthcare Conference: 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:LEGN
• CIK: 1801198
• Web: www.legendbiotech.com
• Phone: 732-317-5050
• Fax: N/A
• Employees: 2,965
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Legend Biotech: $54.69
• High Price Target: $74.00
• Low Price Target: $24.00
• Potential Upside/Downside: +125.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.53
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$296.80 million
• Net Margins: -7.21%
• Pretax Margin: -4.42%
• Return on Equity: -8.71%
• Return on Assets: -5.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.04
• Quick Ratio: 2.94

Sales & Book Value

• Annual Sales: $1.03 billion
• Price / Sales: 4.57
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.43 per share
• Price / Book: 4.47

Miscellaneous

• Outstanding Shares: 193,770,000
• Free Float: 193,730,000
• Market Cap: $4.71 billion
• Optionable: Optionable
• Beta: 0.55